anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Active Low intensity focused ultrasound pulsation (LIFUP) will be administered to the internal globus pallidus while participants are in the MRI scanner. Then, 2 weeks later, sham LIFUP will be administered.
<P>PROBLEM TO BE SOLVED: To provide a color tone change inhibitor suppressing color tone change of quinone coloring matter through including vitamin B2.  <P>SOLUTION: This color tone change inhibitor of quinone coloring matter is formulated with vitamin B2 or its derivative. A form containing the color tone change inhibitor may be liquid medicine or solid medicine, and if liquid medicine, the form is drink or syrup, and if solid medicine, the form is granule, fine grain or tablet. A composition is prevented from color tone change of quinone coloring matter through formulating vitamin B2 or its derivative. A form containing the composition may be liquid medicine or solid medicine, and if liquid medicine, the form is drink or syrup, and if solid medicine, the form is granule, fine grain or tablet. The composition is such one as to be medicine, unregulated drug, health food, food, drink, feed, or the like.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
All injections in VIAFLEX plastic containers are intended for intravenous administration using sterile and nonpyrogenic equipment. 

As directed by a physician. Dosage, rate, and duration of administration are to be individualized and depend upon the indication for use, the patient’s age, weight, clinical condition, concomitant treatment, and on the patient’s clinical and laboratory response to treatment. 

When other electrolytes or medicines are added to this solution, the dosage and the infusion rate will also be dictated by the dose regimen of the additions.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Use of a final filter is recommended during administration of all parenteral solutions, where possible.

Do not administer unless the solution is clear and seal is intact. 

Additives may be incompatible with Sodium Chloride Injection, USP. As with all parenteral solutions, compatibility of the additives with the solution must be assessed before addition. Before adding a substance or medication, verify that it is soluble and/or stable in water and that the pH range of Sodium Chloride Injection, USP is appropriate. After addition, check for unexpected color changes and/or the appearance of precipitates, insoluble complexes or crystals.

The instructions for use of the medication to be added and other relevant literature must be consulted. Additives known or determined to be incompatible must not be used. When introducing additives to Sodium Chloride Injection, USP, aseptic technique must be used. Mix the solution thoroughly when additives have been introduced. Do not store solutions containing additives. 

After opening the container, the contents should be used immediately and should not be stored for a subsequent infusion. Do not reconnect any partially used containers. Discard any unused portion.
The invention discloses a traditional Chinese medicine composition for treating hypertension. The composition is prepared from rhus chinensis, trapa incise root, fennelflower, sculellaria barbata, kudzu vine root, meliosma rigida, fortune windmillpalm flower, lagochuilus platyacanthus rupr, salsola collina, salviae miltiorrhizae, longstamen onion bulb, broadleaf holly leaf, inula flower, common fenugreek seed, lotus plumule, fructus lycii, oyster plant leaf, woolly-fruited glochidion root, thunbergia fragrans and herba andrographitid. The traditional Chinese medicine composition is especially used for treating hypertension, is safe in clinical application and does not irritate organs after being taken. The composition can be used for remarkably improving the curative effect, changing or relieving the drug property and eliminating toxic and side effects of medicines due to the reasonable compatibility of the components. The composition has short treatment cycle and remarkable curative effect. Clinical application researches indicate that the composition has an effective cure rate of 92.6 percent and a total effective rate of 99.5 percent on hypertension.
FIELD: mechanical engineering; internal combustion engines. SUBSTANCE: proposed pump plant can be used in system restraining evaporation of fuel in internal combustion engines. Pump plant used in such system has diaphragm set into operation of electromagnet and magnetic armature and delivery chamber with system of valves. First valve can be placed in communication with ambient air by means of supply pipeline. Second valve can be connected with adsorption filter by means of pressure pipeline. Shutoff valve is installed between supply and pressure pipelines. Pump diaphragm is installed for movement by means of electromagnetic drive. Shutoff valve is electromagnetically controlled. Invention makes it possible to accurately determine the size of leakage hole, reduce cost of mounting, enlarge range of sealing check at all engine operating modes. EFFECT: increased reliability. 13 cl, 6 dwg
The invention relates to composite materials comprising polymer nanofibers and polymer nanoparticles, wherein at least one of the two polymer materials is loaded with a substance selected from therapeutic and diagnostic agents. Fibers and nanoparticles can comprise identical or different polymers; the polymer materials are, however, biocompatible in every case. Therapeutic and diagnostic agents can be hydrophilic or lipophilic and the two polymer materials likewise. The at least one polymer material and the substance with which said material is loaded are either both hydrophilic or both lipophilic. The polymer nanoparticles of the composite materials have a diameter of 10 nm to 600 nm. The polymer fibers have diameters of 10 nm to 50 μm and lengths of 1 μm to several meters. The invention further relates to a method for producing said composite materials. Polymer nanoparticles can be produced in different ways, such as through controlled precipitation of a polymer solution that optionally comprises a loading substance. The nanoparticles are then mixed with another polymer and a loading substance as applicable, depending on whether particles, fibers or both are to be loaded with substance. The processing of this solution into composites comprising polymer fibers polymer nanoparticles can occur by means of electrospinning, melt spinning, extruding or template process. Composite materials according to the invention are suitable for the production of pharmaceuticals that release therapeutically or diagnostically effective substances slowly and in a controlled manner.
A cloud-connected ring-based sensor system includes a ring, a ring-manager application (e.g., running on a mobile device), and cloud services. The ring collects sensor data and forwards it to the app, which forwards it (modified or unmodified) to the cloud services. The cloud services can analyze the data, e.g., to look for trends. The cloud services can provide access to the data and analysis results to a provider, who can then return information (instructions, advice, etc.) to the cloud services, which makes the information available to the ring-wearer via the ring-manager application. The sensor can be a heartbeat sensor. In that case, the ring automatically switches between an active mode and a standby mode depending on whether or not a heartbeat is detected.
Cancer cachexia, characterized by the progressive loss of skeletal muscle mass, leads to functional impairment and poor prognosis. Anamorelin is approved for treating cancer cachexia in Japan; however, the factors influencing its discontinuation and the impact of combining anamorelin with rehabilitation remain unclear. Therefore, we retrospectively analyzed 82 patients with cancer cachexia to identify factors associated with anamorelin discontinuation and assess changes in nutritional status and motor function using non-dominant handgrip strength after 12 wk. Patients received outpatient rehabilitation, combining resistance and aerobic training every two weeks, alongside anamorelin therapy. Our findings indicate that patients with an ECOG performance status of 1 or 2 were less likely to continue anamorelin therapy for 12 wk compared to those with a performance status of 0 (odds ratio 2.71; 95% CI 1.05 - 7.00; p = 0.040). Significant improvements were observed in body weight (48.8 to 53.7 kg, p < 0.001), skeletal muscle mass (6.4 to 6.9 kg/m2, p < 0.001), FAACT score (11.5 to 18.0, p < 0.001), and non-dominant handgrip strength (20.5 to 21.7 kg, p = 0.018) after 12 wk. Early initiation of anamorelin with regular rehabilitation is recommended to enhance nutritional status and motor function in patients with cancer cachexia.
Flurbiprofen sodium is one of a series of phenylalkanoic acids that have shown analgesic, antipyretic, and anti-inflammatory activity in animal inflammatory diseases. Its mechanism of action is believed to be through inhibition of the cyclo-oxygenase enzyme that is essential in the biosynthesis of prostaglandins.

Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed on animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilatation, increased vascular permeability, leukocytosis, and increased intraocular pressure.

Prostaglandins also appear to play a role in the miotic response produced during ocular surgery by constricting the iris sphincter independently of cholinergic mechanisms. In clinical studies, Flurbiprofen Sodium Ophthalmic Solution has been shown to inhibit the miosis induced during the course of cataract surgery.

Results from clinical studies indicate that flurbiprofen sodium has no significant effect upon intraocular pressure.
PURPOSE OF REVIEW: Medical cannabis (MC) has entered mainstream medicine by a unique route. Regulatory acceptance as a medical product in many jurisdictions has bypassed the traditional evidence-based pathway required for therapies. Easier access to MC, especially related to recreational legalization of cannabis, has led to widespread use by patients for symptom relief of a variety of medical conditions and often without medical oversight. Musculoskeletal pain remains the most common reason for MC use. This review examines real-world issues pertaining to MC and offers some guidance for clinical care of patients with rheumatic diseases being treated with MC.
RECENT FINDINGS: Controlled clinical studies of cannabis products in patients with rheumatic diseases have been small and tested a range of compounds, routes of administration, and clinical populations, limiting our ability to generate conclusions on MC's effectiveness in this population. Observational cohort studies and surveys suggest that use of MC and related products in patients with rheumatic diseases improves pain and associated symptoms but is commonly accompanied by mild to moderate side effects. Conflicting evidence contributes to practitioner and patient uncertainty regarding the use of MC for rheumatic disease-related pain. Despite promising preclinical and observational evidence that MC and cannabis-derived compounds are useful in the management of rheumatic disease-related pain, there remains limited high-quality clinical evidence to substantiate these findings. There are a significant number of clinical trials on this topic currently planned or underway, however, suggesting the next decade may yield more clarity. Nevertheless, given that many people with rheumatic diseases are using cannabis products, healthcare professionals must remain apprised of the evidence pertaining to cannabinoids, communicate such evidence to patients in a meaningful way that is free from personal bias and stigma, and maintain strong collaborative clinical care pertaining to MC.
Novel 5-substituted-6-oxo-5,6-dihydropyrido-[2,3-b][1,4] benzoxazepines of the general formula <FORM:1055221/C2/1> (wherein R1 represents a hydrogen or halogen atom or an amino, acylamino, acyl or C1- 5 alkyl or alkoxy group and R2 represents a hydrogen atom, or R1 and R2 together complete a fused-on benzene ring, and R represents a straight or branched alkenyl or haloalkenyl group, or a straight or branched alkyl group optionally substituted by at least one halogen atom, by a C1- 5 alkoxy group, by an aryl group optionally carrying one or more halogen or C1- 5 alkyl or alkoxy substituents, or by a basic group -NR3R4 wherein R3 and R4 represent C1- 5 alkyl groups or jointly form with N a heterocyclic ring which may contain a further heteroatom and/or may be substituted by C1- 5 alkyl groups) are prepared by reacting alkali metal derivatives of the corresponding 5-unsubstituted compounds with compounds RX (wherein X is the residue of a reactive ester).  When R1 in the product is to represent NH2, this group is preferably protected (e.g. by acylation) during the reaction.  Compounds containing a basic substituent may subsequently be converted to acid addition salts.ALSO:Pharmaceutical compositions having antipyretic, anticonvulsive, analgesic and sedative activity comprise, in association with a pharmaceutical carrier or excipient, at least one compound of the general formula:  <FORM:1055221/A5-A6/1> (wherein R1 represents a hydrogen or halogen atom or an amino, acylamino, acyl or C1-5 alkyl or alkoxy group and R2 represents a hydrogen atom, or R1 and R2 together complete a fused-on benzene ring, and R represents a straight or branched alkenyl or haloalkenyl group, or a straight or branched alkyl group optionally substituted by at least one halogen atom, by a C1-5 alkoxy group, by an aryl group optionally carrying one or more halogen or C1-5 alkyl or alkoxy substituents, or by a basic group -NR3R4 wherein R3 and R4 represent C1-5 alkyl groups or jointly form with N a heaterocyclic ring which may contain a further heteroatom and/or may be substituted by C1-5 alkyl groups) or a non-toxic acid addition salt thereof if it contains a basic group.  The preparations are preferably in unit dosage forms suitable for oral, rectal or parenteral administration. They may contain other compatible active ingredients such as sedatives (e.g. phenobaribtone or its sodium salt, or codeine salts), N-(2-amino-3,5-dibromobenzyl)-N-methylcyclohexylammonium chloride, or ascorbic acid.
Conservative surgery in breast cancer is performed more than 50% of cases, however, aesthetic results are suboptimal, because reconstructive techniques are performed in less than 5% of them. Objective: To demonstrate that the placement of a silicone prosthesis in partial defects generated by breast cancer conservative surgery improves the aesthetic result, compared to the usual surgical technique, safely, reproducibly and compatible with adjuvant treatments.

Methodology: Prospective randomized clinical trial, controlled with blind evaluator. Inclusion criteria: Women with breast cancer candidates for conservative surgery. Intervention: In the cases the study technique will be carried out consisting in the filling of the defect with a silicone prosthesis of size adjusted to it (2-4cm). Controls: usual surgical procedure. Main result variable: aesthetic results (visual analog scale) according to the patient, surgeon and blind external evaluator. Secondary variables: surgical complications, local complications derived from adjuvant treatments, rate of local recurrence, rate of reintervention due to affected margins, behavior in mammographic follow-up, professional satisfaction and impact on quality of life.
Hydrocodone bitartrate and homatropine methylbromide oral solution is not recommended for use in pregnant women. Prolonged use of hydrocodone bitartrate and homatropine methylbromide oral solution during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly. Advise pregnant women using opioids for a prolonged period of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. [ see Use in Specific Populations (8.1), Patient Counseling Information (17)]
Systems and methods process images to determine a skin condition severity analysis and to visualize a skin analysis such as using a deep neural network (e.g. a convolutional neural network) where a problem was formulated as a regression task with integer-only labels. Auxiliary classification tasks (for example, comprising gender and ethnicity predictions) are introduced to improve performance. Scoring and other image processing techniques may be used (e.g. in assoc. with the model) to visualize results such as highlighting the analyzed image. It is demonstrated that the visualization of results, which highlight skin condition affected areas, can also provide perspicuous explanations for the model. A plurality (k) of data augmentations may be made to a source image to yield k augmented images for processing. Activation masks (e.g. heatmaps) produced from processing the k augmented images are used to define a final map to visualize the skin analysis.
Replication of the complex retrovirus mouse mammary tumor virus (MMTV) is antagonized by murine Apobec3 (mA3), a member of the Apobec family of cytidine deaminases. We have shown that MMTV-encoded Rem protein inhibits proviral mutagenesis by the Apobec enzyme, activation-induced cytidine deaminase (AID) during viral replication in BALB/c mice. To further study the role of Rem in vivo, we have infected C57BL/6 (B6) mice with a superantigen-independent lymphomagenic strain of MMTV (TBLV-WT) or a mutant strain that is defective in Rem and its cleavage product Rem-CT (TBLV-SD). Compared to BALB/c, B6 mice were more susceptible to TBLV infection and tumorigenesis. Furthermore, unlike MMTV, TBLV induced T-cell tumors in B6 μMT mice, which lack membrane-bound IgM and conventional B-2 cells. At limiting viral doses, loss of Rem expression in TBLV-SD-infected B6 mice accelerated tumorigenesis compared to TBLV-WT in either wild-type B6 or AID-knockout mice. Unlike BALB/c results, high-throughput sequencing indicated that proviral G-to-A or C-to-T mutations were unchanged regardless of Rem expression in B6 tumors. However, knockout of both AID and mA3 reduced G-to-A mutations. Ex vivo stimulation showed higher levels of mA3 relative to AID in B6 compared to BALB/c splenocytes, and effects of agonists differed in the two strains. RNA-Seq revealed increased transcripts related to growth factor and cytokine signaling in TBLV-SD-induced tumors relative to TBLV-WT-induced tumors, consistent with another Rem function. Thus, Rem-mediated effects on tumorigenesis in B6 mice are independent of Apobec-mediated proviral hypermutation.
Establishment of a database of healthy control imaging values (n=20 per decade, range 40 to 80yrs). A database of healthy control values will be established for each technology taking into account extraneous factors such as age (range 40 to 70 years) and gender. The healthy control database will be compared to the results of each individual patient in the prospective study phase of this proposed Research Program (see Prospective Study Phase, 3, Control group). Statistical confidence limits for abnormality at each time point, and for progression overtime, will be established. Measurements will be repeated at separate visits to establish repeatability.
Background To describe the changes in cervical lesions prevalence and high-risk human papillomavirus (HR-HPV) infections from 2012 to 2021, which have never been reported before, to provide direction for the effective implementation of cervical cancer prevention measures. Methods This retrospective study included women aged >25years who received either organised or opportunistic cervical HR-HPV screening from January 2012 to December 2021 in Karamay Central Hospital, Karamay, China. The patients were split into four groups according to age 25-35, 36-45, 46-55 and >55years, respectively. The Joinpoint Regression Program was used to analyse the trends of HR-HPV infection and the detection of cervical lesions. Results Data from 85,429 women revealed a decline in HR-HPV infection rates across all age groups from 2012 to 2021. Although HR-HPV infection rates decreased, cervical lesion detection rates increased, although the proportion of cervical cancer in these lesions declined, likely due to enhanced awareness and HPV vaccination in Karamay. From 2012 to 2021, the prevalence of low-grade squamous intraepithelial lesions was 9.70%, and high-grade squamous intraepithelial lesions was 5.85%. HR-HPV infections were highest in the ≥55years age group, with HPV52 (20.96%) being the most prevalent type. Conclusions In the past 10years, the prevalence of HR-HPV infection has shown a decreasing trend, whereas the detection prevalence of cervical lesions has shown an upward trend among women in Karamay City. Importantly, particular emphasis should be placed on cervical cancer screening in women aged >55years.
All operations were performed or supervised by the same surgeon. Right after the patients in mini-PNL group were placed a 5F ureteral catheter with general anesthesia, they were had a prone position and the access was performed by choosing the optimal calyx to reach the stone following the contrast agent was given. The guide wire was then placed and the stones were broken with a laser lithotripter using a 12F nephroscope (Modular minimally invasive PCNL system, Karl Storz, Tuttlingen, Germany) following the dilatation using an one step dilator with a 16.5F access sheath. When necessary, stones were removed using the stone removal forceps. Right after a 14-Fr nephrostomy tube was inserted and an antegrade pyelography was taken, the operation was terminated.
With support from the MADRC ORE Core, we will recruit 30 community-dwelling older adults to conduct an open pilot study of PeersCOG. Trained and supervised peer coaches will deliver depression care to adults 60 years of age and older with depression and subjective cognitive decline in an 8-week intervention using video chats and texts. We will use mixed methods to assess feasibility, acceptability, and fidelity. We will use validated instruments to assess the preliminary outcomes, including depression, SCD, functioning, and social factors at baseline, 8 weeks, and 3 months, and we will conduct post-intervention interviews with stakeholders at 8 weeks. Older adult participants will be asked to name a study partner who will support the older adult throughout the study in terms of study enrollment. They may also have additional perspectives on the impact of impaired cognition and depression on daily living and related needs. The older adult will not be excluded if the study partner is not available.